Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Total Non-Current Liabilities (2016 - 2025)

IGC Pharma (IGC) has disclosed Total Non-Current Liabilities for 15 consecutive years, with $137000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 27.89% to $137000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $137000.0, a 27.89% decrease, with the full-year FY2025 number at $160000.0, down 33.61% from a year prior.
  • Total Non-Current Liabilities was $137000.0 for Q3 2025 at IGC Pharma, down from $140000.0 in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $696000.0 in Q1 2021 to a low of $137000.0 in Q3 2025.
  • A 5-year average of $353842.1 and a median of $340000.0 in 2023 define the central range for Total Non-Current Liabilities.
  • Biggest YoY gain for Total Non-Current Liabilities was 38.92% in 2021; the steepest drop was 46.73% in 2021.
  • IGC Pharma's Total Non-Current Liabilities stood at $534000.0 in 2021, then dropped by 25.66% to $397000.0 in 2022, then crashed by 31.99% to $270000.0 in 2023, then crashed by 40.0% to $162000.0 in 2024, then fell by 15.43% to $137000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Total Non-Current Liabilities are $137000.0 (Q3 2025), $140000.0 (Q2 2025), and $160000.0 (Q1 2025).